vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and BRANDYWINE REALTY TRUST (BDN). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $127.0M, roughly 1.1× BRANDYWINE REALTY TRUST). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -38.4%, a 73.9% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 4.5%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 0.7%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Brandywine Realty Trust is a Philadelphia-based real estate investment trust (REIT) that invests in office buildings in Philadelphia, Washington, D.C., and Austin, Texas.
ADMA vs BDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $127.0M |
| Net Profit | $49.4M | $-48.8M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 1.2% |
| Net Margin | 35.5% | -38.4% |
| Revenue YoY | 18.4% | 4.5% |
| Net Profit YoY | -55.9% | -80.4% |
| EPS (diluted) | $0.20 | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $127.0M | ||
| Q4 25 | $139.2M | $121.0M | ||
| Q3 25 | $134.2M | $121.4M | ||
| Q2 25 | $122.0M | $120.6M | ||
| Q1 25 | $114.8M | $121.5M | ||
| Q4 24 | $117.5M | $121.9M | ||
| Q3 24 | $119.8M | $131.8M | ||
| Q2 24 | $107.2M | $125.3M |
| Q1 26 | — | $-48.8M | ||
| Q4 25 | $49.4M | $-36.7M | ||
| Q3 25 | $36.4M | $-25.9M | ||
| Q2 25 | $34.2M | $-88.7M | ||
| Q1 25 | $26.9M | $-27.0M | ||
| Q4 24 | $111.9M | $-44.5M | ||
| Q3 24 | $35.9M | $-165.2M | ||
| Q2 24 | $32.1M | $30.2M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | 61.3% | ||
| Q3 25 | 56.3% | 62.6% | ||
| Q2 25 | 55.1% | 62.4% | ||
| Q1 25 | 53.2% | 60.8% | ||
| Q4 24 | 53.9% | 61.2% | ||
| Q3 24 | 49.8% | 64.9% | ||
| Q2 24 | 53.6% | 63.1% |
| Q1 26 | — | 1.2% | ||
| Q4 25 | 45.1% | 22.8% | ||
| Q3 25 | 38.0% | 20.8% | ||
| Q2 25 | 35.1% | -34.3% | ||
| Q1 25 | 30.4% | 12.5% | ||
| Q4 24 | 32.6% | 18.0% | ||
| Q3 24 | 33.1% | -7.2% | ||
| Q2 24 | 36.6% | 15.5% |
| Q1 26 | — | -38.4% | ||
| Q4 25 | 35.5% | -30.3% | ||
| Q3 25 | 27.1% | -21.3% | ||
| Q2 25 | 28.1% | -73.5% | ||
| Q1 25 | 23.4% | -22.2% | ||
| Q4 24 | 95.2% | -36.5% | ||
| Q3 24 | 30.0% | -125.4% | ||
| Q2 24 | 29.9% | 24.1% |
| Q1 26 | — | $-0.28 | ||
| Q4 25 | $0.20 | $-0.21 | ||
| Q3 25 | $0.15 | $-0.15 | ||
| Q2 25 | $0.14 | $-0.51 | ||
| Q1 25 | $0.11 | $-0.16 | ||
| Q4 24 | $0.45 | $-0.25 | ||
| Q3 24 | $0.15 | $-0.96 | ||
| Q2 24 | $0.13 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $36.2M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | — |
| Total Assets | $624.2M | $3.6B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $36.2M | ||
| Q4 25 | $87.6M | $32.3M | ||
| Q3 25 | $61.4M | $75.5M | ||
| Q2 25 | $90.3M | $122.6M | ||
| Q1 25 | $71.6M | $29.4M | ||
| Q4 24 | $103.1M | $90.2M | ||
| Q3 24 | $86.7M | $36.5M | ||
| Q2 24 | $88.2M | $30.4M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | $2.6B | ||
| Q3 25 | $72.4M | $2.3B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | $72.3M | $2.2B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | — | — | ||
| Q4 25 | $477.3M | $792.7M | ||
| Q3 25 | $431.2M | $841.5M | ||
| Q2 25 | $398.3M | $879.8M | ||
| Q1 25 | $373.4M | $993.6M | ||
| Q4 24 | $349.0M | $1.0B | ||
| Q3 24 | $231.9M | $1.1B | ||
| Q2 24 | $188.3M | $1.3B |
| Q1 26 | — | $3.6B | ||
| Q4 25 | $624.2M | $3.6B | ||
| Q3 25 | $568.7M | $3.3B | ||
| Q2 25 | $558.4M | $3.4B | ||
| Q1 25 | $510.6M | $3.4B | ||
| Q4 24 | $488.7M | $3.5B | ||
| Q3 24 | $390.6M | $3.6B | ||
| Q2 24 | $376.4M | $3.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | 3.23× | ||
| Q3 25 | 0.17× | 2.70× | ||
| Q2 25 | — | 2.63× | ||
| Q1 25 | — | 2.23× | ||
| Q4 24 | 0.21× | 2.13× | ||
| Q3 24 | — | 2.06× | ||
| Q2 24 | — | 1.73× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $116.7M | ||
| Q3 25 | $13.3M | $47.5M | ||
| Q2 25 | $21.1M | $34.4M | ||
| Q1 25 | $-19.7M | $6.3M | ||
| Q4 24 | $50.2M | $181.1M | ||
| Q3 24 | $25.0M | $52.2M | ||
| Q2 24 | $45.6M | $48.2M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | 1.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
BDN
| Rents | $120.7M | 95% |
| Third party management fees, labor reimbursement and leasing | $4.7M | 4% |
